Sergelyne Cadet-Valeus
Internal Medicine · Arverne, NYNPI 1053688671
Payments from drug & device makers
Across 452 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Neurocrine Biosciences, Inc.$1K
- Novo Nordisk$925
- AstraZeneca$912
- Lilly USA, LLC$714
- Pfizer$511
- plus $4K from 34 others
What the payments were for
- Food & beverage$9,51198%
- Education$1722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,620 |
| Neurocrine Biosciences, Inc. | 54 | $1,288 |
| Novo Nordisk | 60 | $925 |
| AstraZeneca | 47 | $912 |
| Lilly USA, LLC | 39 | $714 |
| Pfizer | 26 | $511 |
| Merck | 24 | $453 |
| GSK | 21 | $387 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $384 |
| Teva Pharmaceuticals USA, Inc. | 11 | $284 |
| Exact Sciences | 12 | $243 |
| Bayer | 5 | $212 |
| Viiv Healthcare Company | 6 | $172 |
| SK Life Science, Inc. | 1 | $164 |
| Eisai Inc. | 3 | $159 |
| Dexcom, Inc. | 4 | $154 |
| Johnson & Johnson(2 entities) | 7 | $134 |
| Boehringer Ingelheim | 6 | $117 |
| Amarin Pharma, Inc. | 5 | $94 |
| Novartis | 4 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $66 |
| Abbott | 3 | $60 |
| Renalytix AI, Inc. | 3 | $56 |
| Global Blood Therapeutics, Inc. | 2 | $47 |
| Gilead | 2 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Phadia US Inc. | 2 | $41 |
| Philips North America LLC | 2 | $41 |
| Amgen | 2 | $40 |
| Ironwood Pharmaceuticals, Inc | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Vertex | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Indivior Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$164
- NURTEC ODT$139
- Leqembi$125
- Kerendia$118
- VRAYLAR$112
How this compares
$9,683 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 143 | $194,249 |
| FarxigaDapagliflozin Propanediol | 142 | $141,793 |
| OzempicSemaglutide | 85 | $126,576 |
| LofenaDiclofenac Potassium | 16 | $96,439 |
| LinzessLinaclotide | 66 | $74,016 |
| JardianceEmpagliflozin | 48 | $58,228 |
| TrulicityDulaglutide | 23 | $45,522 |
| MounjaroTirzepatide | 24 | $41,485 |
| EliquisApixaban | 40 | $40,332 |
| Diclofenac Potassium | 15 | $33,747 |
| UbrelvyUbrogepant | 18 | $30,876 |
| QuliptaAtogepant | 22 | $30,556 |
| TradjentaLinagliptin | 34 | $27,720 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $22,053 |
| KerendiaFinerenone | 16 | $21,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $925 | $320,825228 claims |
| AstraZenecaFarxiga | $912 | $141,793142 claims |
| AbbVieLinzess, Ubrelvy, Qulipta | $1,620 | $135,447106 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $714 | $87,00847 claims |
| Boehringer IngelheimJardiance, Tradjenta | $117 | $85,94882 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Shingrix | $387 | $41,61684 claims |
| PfizerEliquis | $511 | $40,33240 claims |
| MerckJanumet | $453 | $22,05320 claims |
| BayerKerendia | $212 | $21,29216 claims |
| NovartisEntresto | $78 | $16,65615 claims |
| Johnson & JohnsonXarelto | $134 | $10,02015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Arverne
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.